Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joanna Chon

Urogynecology and Reconstructive Pelvic Surgery Naples, FL Medical Doctor

NPI 1477602068 CMS profile 111925

1035 Piper Blvd Ste 101, Naples, FL 34110

Open in the dashboard

General payments

$9,148

274 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joanna Chon of Naples, FL is reported in the CMS Open Payments database as having received $9,148 across 274 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 56th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,872 98
2024 General $596 21
2023 General $1,390 41
2022 General $674 22
2021 General $1,789 39
2020 General $337 31
2019 General $490 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joanna Chon
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Joanna Chon were reported at $3,872. Among 149 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $779 and the middle half received between $301 and $2,705.

Show as a table
Year Joanna Chon Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $490 $799 $319–$2,013 $163
2020 $337 $384 $158–$1,360 $114
2021 $1,789 $641 $247–$2,515 $132
2022 $674 $843 $347–$2,794 $149
2023 $1,390 $819 $308–$2,302 $160
2024 $596 $882 $306–$2,459 $164
2025 $3,872 $779 $301–$2,705 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Axonics Modulation Technologies, Inc. $2,331 70 payments
  2. Astellas Pharma US Inc $987 39 payments
  3. Medtronic, Inc. $636 5 payments
  4. Janssen Biotech, Inc. $509 19 payments
  5. Coloplast Corp $449 14 payments
  6. Boston Scientific Corporation $404 5 payments
  7. Ferring Pharmaceuticals Inc. $356 9 payments
  8. Urogen Pharma, Inc. $335 7 payments
  9. PROCEPT BioRobotics Corporation $243 5 payments
  10. AbbVie, Inc. $234 11 payments
  11. Other $2,665 90 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,214 264 payments
  2. Travel and Lodging $1,490 5 payments
  3. Education $444 5 payments
Products named General payments · program years 2019–2025
  1. Bulkamid $1,415 13 payments
  2. Axonics r-SNM System Urology $1,265 19 payments
  3. Axonics $1,197 30 payments
  4. ALTAVIVA $636 5 payments
  5. MYRBETRIQ $403 24 payments
  6. XTANDI $391 23 payments
  7. ERLEADA $363 17 payments
  8. ADSTILADRIN $356 9 payments
  9. Axonics r-SNM System Urology $223 24 payments
  10. BOTOX $211 10 payments
  11. Other $4,618 145 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

2,906

Median for Urology: 1,053

Drug cost

$468,465

Median for Urology: $101,464

Branded share of claims

30.3%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 250 $213,417
Gemtesa Vibegron Brand 154 $154,173
Estradiol Generic 511 $28,005
Solifenacin Succinate Generic 573 $20,876
Methenamine Hippurate Generic 143 $9,728
Mirabegron Er Mirabegron Brand 11 $6,852
Tolterodine Tartrate Er Tolterodine Tartrate Brand 101 $6,834
Fesoterodine Fumarate Er Fesoterodine Fumarate Brand 68 $5,902
Darifenacin Er Darifenacin Hydrobromide Brand 12 $4,542
Trospium Chloride Er Trospium Chloride Brand 37 $4,408

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$337,616

Of which drugs: $28,821

Medicare patients

834

Average age 78

Services billed

18,406

680 women, 154 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Ischemic heart disease 36%
Osteoporosis 32%
Chronic kidney disease 25%
Depression 24%
Cancer 23%
Atrial fibrillation 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 25 5,301 $26,425
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 35 7,000 $657

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTANDI
  • Astellas Pharma US Inc $29
$29 — —
MYRBETRIQ
  • Astellas Pharma US Inc $26
$26 250 —
POSLUMA
  • Blue Earth Diagnostics Limited $24
$24 — —
XIAFLEX
  • Endo USA, Inc. $24
$24 — —
Nubeqa
  • Bayer HealthCare Pharmaceuticals Inc. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

274 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record